SMMT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Summit Therapeutics Inc (SMMT) does not present a strong buy opportunity for a beginner, long-term investor at this moment. While there are positive catalysts such as the potential of its ivonescimab drug and a favorable analyst rating from Stifel, the technical indicators suggest the stock is overbought, and there is no strong signal from Intellectia Proprietary Trading Signals. Additionally, financial performance remains weak, and there are mixed analyst opinions with significant risks tied to upcoming catalysts.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 92.102, signaling the stock is overbought. Moving averages are converging, suggesting indecision in price trends. The stock is trading near resistance levels (R2: 24.825), which may limit further upside in the short term.
Stifel's Buy rating with a $45 price target highlights the potential of ivonescimab in a $200B drug class. The HARMONi-3 squamous cohort data in Q2 could revitalize the stock and lead to rapid FDA engagement.
Jefferies downgraded the stock to Hold with a reduced price target of $15, citing risks in upcoming catalysts and challenges in translating China-to-global data. H.C. Wainwright also lowered its price target due to uncertainty around HARMONi-2 and HARMONi-6 analyses.
In 2025/Q4, revenue remained at $0 with no growth. Net income improved to -$219.17M (up 258.11% YoY), and EPS increased to -0.29 (up 262.50% YoY). However, the company remains unprofitable with no gross margin.
Analyst ratings are mixed. Stifel initiated coverage with a Buy rating and a $45 price target, citing strong competitive positioning. However, Jefferies downgraded the stock to Hold with a $15 price target, citing risks in upcoming catalysts. H.C. Wainwright also lowered its price target to $30, citing near-term uncertainties.
